Devonian Health Group Inc. (TSXV:GSD)

Canada flag Canada · Delayed Price · Currency is CAD
13.75
0.00 (0.00%)
Mar 5, 2026, 9:30 AM EST
4.17%
Market Cap 38.03M
Revenue (ttm) 18.52M
Net Income (ttm) -6.97M
Shares Out 2.77M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 1,589
Open 13.75
Previous Close 13.75
Day's Range 13.75 - 13.75
52-Week Range 5.10 - 15.00
Beta 1.47
RSI 57.66
Earnings Date Mar 27, 2026

About Devonian Health Group

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Andre Boulet
Employees 11
Stock Exchange TSX Venture Exchange
Ticker Symbol GSD
Full Company Profile

Financial Performance

In fiscal year 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.

Financial Statements

News

There is no news available yet.